ESR1 and breast cancer: As of August 2024, we now have multiple projects in progress, including but not limited to research efforts looking at dormancy, genomic structural evolution, leptomeningeal metastasis, expansion of PDX model development to look at specific drug resistance models, ESR1 mutant effects in the liver microenvironment, and international collaborations at the clinical and molecular history of changes in breast cancer subtypes such as ILC with the UPTIDER program [20].